{"id":534754,"date":"2021-09-07T08:04:27","date_gmt":"2021-09-07T12:04:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/"},"modified":"2021-09-07T08:04:27","modified_gmt":"2021-09-07T12:04:27","slug":"akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/","title":{"rendered":"Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Sept.  07, 2021  (GLOBE NEWSWIRE) &#8212; Akero Therapeutics,\u00a0Inc.\u00a0(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at the Morgan Stanley Virtual Global Healthcare Conference on Wednesday, September 15, 2021 at 11:45 a.m. (ET).<\/p>\n<p>A live webcast of the Company presentation will be available through the investor relations section of the Company&#8217;s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wBIA3_xDeUII9bvjo9pnYDiZgfhBFDyj0ncKGKwlNJER5bMzBaIFmfWJ7n9jQrHc0hlWbidAOV88olnExfBzS8Ez46qxzelZi_X02uqgOGFCCmpTsaPb1yrx_qFQkWRSAfg_UZInc2pd57t1nwGA8gL-qVYlL3DNubIa2F1mrUHo1EDyPCsko6KQ0ZuNVMADq1PPeX73-DcEBMJ6f7URZQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.akerotx.com<\/a>. Following the live webcasts, archived replays will be available on the Company&#8217;s website.<\/p>\n<p>\n        <strong>About Akero Therapeutics<\/strong><br \/>\n        <br \/>Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero\u2019s investigational drug product candidate, efruxifermin (EFX) is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of effects observed in clinical studies position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in pre-cirrhotic patients with F2\/F3 fibrosis and the SYMMETRY study in cirrhotic (F4) patients. Akero is headquartered in South San Francisco. Visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wBIA3_xDeUII9bvjo9pnYGXY8xl-2mU0PmCVyZoo-x_bpAY3Y0ZfFj3e4wP1eX-sZiuP6BwfMQ-1Z4BsjZyDWw==\" rel=\"nofollow noopener\" target=\"_blank\">www.akerotx.com<\/a> for more information.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Christina Tartaglia<br \/>Stern Investor Relations, Inc.<br \/>212.362.1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b1_h5Qu0q3UEWt0eX6IcrfzuJ4Qm1nOYR3XvTZTWP3MxsJPjt9hvGEPuQSdJz1sVP0T4GITg6uZmp0yvE8sEJoIpzJHQ1FkxBXfmoKBIwPHClMLyVV4flzG3AwU9ayuC\" rel=\"nofollow noopener\" target=\"_blank\">christina.tartaglia@sternir.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>650.487.6488<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZkDysaKSbal9cd2WJl2kwIvdgSNgH7UMUoBbDq32v_5DYHZp-7Hz92_40ttYUae_gHYqgR4ZjcKk_taGMVgcDQ==\" rel=\"nofollow noopener\" target=\"_blank\">media@akerotx.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTAxNyM0MzkxNTQyIzIxODM3NzU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2EzYjNjZmEtMmIxOC00OTBiLWE0MGEtYjJjMDkxNzU4MjU0LTExOTUzMzM=\/tiny\/Akero-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) &#8212; Akero Therapeutics,\u00a0Inc.\u00a0(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at the Morgan Stanley Virtual Global Healthcare Conference on Wednesday, September 15, 2021 at 11:45 a.m. (ET). A live webcast of the Company presentation will be available through the investor relations section of the Company&#8217;s website at\u00a0www.akerotx.com. Following the live webcasts, archived replays will be available on the Company&#8217;s website. About Akero Therapeutics Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero\u2019s investigational drug product candidate, efruxifermin (EFX) is a differentiated Fc-FGF21 fusion protein &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534754","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) &#8212; Akero Therapeutics,\u00a0Inc.\u00a0(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at the Morgan Stanley Virtual Global Healthcare Conference on Wednesday, September 15, 2021 at 11:45 a.m. (ET). A live webcast of the Company presentation will be available through the investor relations section of the Company&#8217;s website at\u00a0www.akerotx.com. Following the live webcasts, archived replays will be available on the Company&#8217;s website. About Akero Therapeutics Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero\u2019s investigational drug product candidate, efruxifermin (EFX) is a differentiated Fc-FGF21 fusion protein &hellip; Continue reading &quot;Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-07T12:04:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTAxNyM0MzkxNTQyIzIxODM3NzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference\",\"datePublished\":\"2021-09-07T12:04:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/\"},\"wordCount\":253,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTAxNyM0MzkxNTQyIzIxODM3NzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/\",\"name\":\"Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTAxNyM0MzkxNTQyIzIxODM3NzU=\",\"datePublished\":\"2021-09-07T12:04:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTAxNyM0MzkxNTQyIzIxODM3NzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTAxNyM0MzkxNTQyIzIxODM3NzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) &#8212; Akero Therapeutics,\u00a0Inc.\u00a0(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at the Morgan Stanley Virtual Global Healthcare Conference on Wednesday, September 15, 2021 at 11:45 a.m. (ET). A live webcast of the Company presentation will be available through the investor relations section of the Company&#8217;s website at\u00a0www.akerotx.com. Following the live webcasts, archived replays will be available on the Company&#8217;s website. About Akero Therapeutics Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero\u2019s investigational drug product candidate, efruxifermin (EFX) is a differentiated Fc-FGF21 fusion protein &hellip; Continue reading \"Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-07T12:04:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTAxNyM0MzkxNTQyIzIxODM3NzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference","datePublished":"2021-09-07T12:04:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/"},"wordCount":253,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTAxNyM0MzkxNTQyIzIxODM3NzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/","name":"Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTAxNyM0MzkxNTQyIzIxODM3NzU=","datePublished":"2021-09-07T12:04:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTAxNyM0MzkxNTQyIzIxODM3NzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTAxNyM0MzkxNTQyIzIxODM3NzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534754"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534754\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}